新型环丙沙星-二羧酸盐口服液制剂对雌性白化大鼠的毒性评价:血液学、生化和组织病理学参数

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Sadat Abdulla Aziz, Twana Mohammed M. Ways, Thomas Hibbard, Mohammed Tofiq Salih, Goran Mohammed Raouf, Kenneth Shankland, Hisham Al-Obaidi
{"title":"新型环丙沙星-二羧酸盐口服液制剂对雌性白化大鼠的毒性评价:血液学、生化和组织病理学参数","authors":"Sadat Abdulla Aziz,&nbsp;Twana Mohammed M. Ways,&nbsp;Thomas Hibbard,&nbsp;Mohammed Tofiq Salih,&nbsp;Goran Mohammed Raouf,&nbsp;Kenneth Shankland,&nbsp;Hisham Al-Obaidi","doi":"10.1007/s12247-025-10079-4","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to evaluate and compare the systemic toxicity profiles of novel ciprofloxacin salts synthesised using dicarboxylic acid counterions. To our knowledge, this represents the first in vivo comparative toxicity assessment of these specific crystalline ciprofloxacin–dicarboxylic acid salts. These salts represent previously unreported solid forms of ciprofloxacin with enhanced solubility and potential for improved oral bioavailability. Albino rats were administered oral liquid formulations, and systemic effects were assessed through haematological, biochemical, and histopathological evaluations.</p><h3>Methods</h3><p>Aqueous Liquid dispersions of ciprofloxacin salts with succinic, glutaric, adipic, and pimelic acids were prepared and orally administered to female albino rats at doses equivalent to 20 mg/kg (low dose) and 60 mg/kg (high dose) of ciprofloxacin for 14 consecutive days. Haematological, biochemical, and histopathological assessments were conducted to determine systemic toxicity. A composite toxicity score was calculated based on percentage deviations from control values in key biochemical markers, and a Z-score heatmap was generated to visualize overall trends.</p><h3>Results</h3><p>Haematological analysis revealed no significant changes in RBC and WBC counts or platelet levels. Biochemical evaluations showed only mild alterations in liver and kidney function markers, lipid profiles, and hormonal levels, largely comparable to the control group. Notably, the GAH and AAH groups exhibited significantly elevated AST and ALT levels compared to the control group (<i>P</i> &lt; 0.05). AST levels in the GAH, AAH, and control groups were 459.00 ± 52.37, 467.33 ± 159.75, and 113.33 ± 32.25 U/L, and ALT levels were 62.33 ± 13.65, 65.00 ± 11.36, and 33.67 ± 11.93 U/L, respectively. The composite toxicity score identified the glutaric acid (GAH) and adipic acid (AAH) salts at high doses as having the most systemic impact (72.4% and 71.95%, respectively), while the pimelic acid salt at high dose (PAH, 21.27%) and adipic acid salt at low dose (AAL, 15.78%) were among the safest. Z-score heatmap analysis supported these findings. Histopathological examination revealed no significant pathological changes in the spleen, kidney, or heart, though minor liver changes were observed.</p><h3>Conclusion</h3><p>The novel ciprofloxacin dicarboxylic acid salts demonstrated a favorable safety profile in rats, with minimal systemic toxicity and only mild histological liver alterations at higher doses. These findings provide important foundational preclinical safety data, supporting further development of these novel salt forms as potentially safer and more bioavailable ciprofloxacin formulations.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 5","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Toxicity Assessment of Oral Liquid Formulations of Novel Ciprofloxacin-Dicarboxylic Acid Salts in Female Albino Rats: Haematological, Biochemical, and Histopathological Parameters\",\"authors\":\"Sadat Abdulla Aziz,&nbsp;Twana Mohammed M. Ways,&nbsp;Thomas Hibbard,&nbsp;Mohammed Tofiq Salih,&nbsp;Goran Mohammed Raouf,&nbsp;Kenneth Shankland,&nbsp;Hisham Al-Obaidi\",\"doi\":\"10.1007/s12247-025-10079-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>This study aimed to evaluate and compare the systemic toxicity profiles of novel ciprofloxacin salts synthesised using dicarboxylic acid counterions. To our knowledge, this represents the first in vivo comparative toxicity assessment of these specific crystalline ciprofloxacin–dicarboxylic acid salts. These salts represent previously unreported solid forms of ciprofloxacin with enhanced solubility and potential for improved oral bioavailability. Albino rats were administered oral liquid formulations, and systemic effects were assessed through haematological, biochemical, and histopathological evaluations.</p><h3>Methods</h3><p>Aqueous Liquid dispersions of ciprofloxacin salts with succinic, glutaric, adipic, and pimelic acids were prepared and orally administered to female albino rats at doses equivalent to 20 mg/kg (low dose) and 60 mg/kg (high dose) of ciprofloxacin for 14 consecutive days. Haematological, biochemical, and histopathological assessments were conducted to determine systemic toxicity. A composite toxicity score was calculated based on percentage deviations from control values in key biochemical markers, and a Z-score heatmap was generated to visualize overall trends.</p><h3>Results</h3><p>Haematological analysis revealed no significant changes in RBC and WBC counts or platelet levels. Biochemical evaluations showed only mild alterations in liver and kidney function markers, lipid profiles, and hormonal levels, largely comparable to the control group. Notably, the GAH and AAH groups exhibited significantly elevated AST and ALT levels compared to the control group (<i>P</i> &lt; 0.05). AST levels in the GAH, AAH, and control groups were 459.00 ± 52.37, 467.33 ± 159.75, and 113.33 ± 32.25 U/L, and ALT levels were 62.33 ± 13.65, 65.00 ± 11.36, and 33.67 ± 11.93 U/L, respectively. The composite toxicity score identified the glutaric acid (GAH) and adipic acid (AAH) salts at high doses as having the most systemic impact (72.4% and 71.95%, respectively), while the pimelic acid salt at high dose (PAH, 21.27%) and adipic acid salt at low dose (AAL, 15.78%) were among the safest. Z-score heatmap analysis supported these findings. Histopathological examination revealed no significant pathological changes in the spleen, kidney, or heart, though minor liver changes were observed.</p><h3>Conclusion</h3><p>The novel ciprofloxacin dicarboxylic acid salts demonstrated a favorable safety profile in rats, with minimal systemic toxicity and only mild histological liver alterations at higher doses. These findings provide important foundational preclinical safety data, supporting further development of these novel salt forms as potentially safer and more bioavailable ciprofloxacin formulations.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>\",\"PeriodicalId\":656,\"journal\":{\"name\":\"Journal of Pharmaceutical Innovation\",\"volume\":\"20 5\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Innovation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12247-025-10079-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10079-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的评价和比较用二羧酸反离子合成的新型环丙沙星盐的全身毒性。据我们所知,这代表了这些特定晶体环丙沙星-二羧酸盐的第一个体内比较毒性评估。这些盐是以前未报道的环丙沙星固体形式,具有增强的溶解度和改善口服生物利用度的潜力。给予白化大鼠口服液体制剂,并通过血液学,生化和组织病理学评估系统效果。方法制备含琥珀酸、戊二酸、己二酸和戊二酸的环丙沙星盐水分散液,分别以环丙沙星20 mg/kg(低剂量)和60 mg/kg(高剂量)给雌性白化大鼠口服,连续14 d。进行血液学、生化和组织病理学评估以确定全身毒性。根据关键生化标志物与控制值的百分比偏差计算复合毒性评分,并生成z评分热图以显示总体趋势。结果血液学分析显示红细胞、白细胞计数及血小板水平无明显变化。生化评估显示,在肝肾功能指标、脂质谱和激素水平上只有轻微的改变,与对照组基本相当。值得注意的是,与对照组相比,GAH和AAH组AST和ALT水平显著升高(P < 0.05)。GAH组、AAH组和对照组AST水平分别为459.00±52.37、467.33±159.75、113.33±32.25 U/L, ALT水平分别为62.33±13.65、65.00±11.36、33.67±11.93 U/L。综合毒性评分显示,高剂量戊二酸(GAH)和己二酸(AAH)盐对全身的影响最大(分别为72.4%和71.95%),而高剂量戊二酸盐(PAH, 21.27%)和低剂量己二酸盐(AAL, 15.78%)最安全。Z-score热图分析支持这些发现。组织病理学检查显示脾、肾、心无明显病理改变,肝脏有轻微改变。结论新型环丙沙星二羧酸盐在大鼠体内具有良好的安全性,在高剂量下具有极小的全身毒性和轻微的肝脏组织学改变。这些发现提供了重要的基础临床前安全性数据,支持进一步开发这些新型盐形式,使其成为更安全、生物利用度更高的环丙沙星配方。图形抽象
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Toxicity Assessment of Oral Liquid Formulations of Novel Ciprofloxacin-Dicarboxylic Acid Salts in Female Albino Rats: Haematological, Biochemical, and Histopathological Parameters

Purpose

This study aimed to evaluate and compare the systemic toxicity profiles of novel ciprofloxacin salts synthesised using dicarboxylic acid counterions. To our knowledge, this represents the first in vivo comparative toxicity assessment of these specific crystalline ciprofloxacin–dicarboxylic acid salts. These salts represent previously unreported solid forms of ciprofloxacin with enhanced solubility and potential for improved oral bioavailability. Albino rats were administered oral liquid formulations, and systemic effects were assessed through haematological, biochemical, and histopathological evaluations.

Methods

Aqueous Liquid dispersions of ciprofloxacin salts with succinic, glutaric, adipic, and pimelic acids were prepared and orally administered to female albino rats at doses equivalent to 20 mg/kg (low dose) and 60 mg/kg (high dose) of ciprofloxacin for 14 consecutive days. Haematological, biochemical, and histopathological assessments were conducted to determine systemic toxicity. A composite toxicity score was calculated based on percentage deviations from control values in key biochemical markers, and a Z-score heatmap was generated to visualize overall trends.

Results

Haematological analysis revealed no significant changes in RBC and WBC counts or platelet levels. Biochemical evaluations showed only mild alterations in liver and kidney function markers, lipid profiles, and hormonal levels, largely comparable to the control group. Notably, the GAH and AAH groups exhibited significantly elevated AST and ALT levels compared to the control group (P < 0.05). AST levels in the GAH, AAH, and control groups were 459.00 ± 52.37, 467.33 ± 159.75, and 113.33 ± 32.25 U/L, and ALT levels were 62.33 ± 13.65, 65.00 ± 11.36, and 33.67 ± 11.93 U/L, respectively. The composite toxicity score identified the glutaric acid (GAH) and adipic acid (AAH) salts at high doses as having the most systemic impact (72.4% and 71.95%, respectively), while the pimelic acid salt at high dose (PAH, 21.27%) and adipic acid salt at low dose (AAL, 15.78%) were among the safest. Z-score heatmap analysis supported these findings. Histopathological examination revealed no significant pathological changes in the spleen, kidney, or heart, though minor liver changes were observed.

Conclusion

The novel ciprofloxacin dicarboxylic acid salts demonstrated a favorable safety profile in rats, with minimal systemic toxicity and only mild histological liver alterations at higher doses. These findings provide important foundational preclinical safety data, supporting further development of these novel salt forms as potentially safer and more bioavailable ciprofloxacin formulations.

Graphical Abstract

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信